jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
Journal of Young PharmacistsNOW IN
Article

Topiramate: Safety in migraine patients

M. Ahamada Safna Mariyam1★, Suchandra Sen2, K. Vijayan3★ Corresponding author

  1. 1Department of Pharmacy Practice, Nandha College of Pharmacy, Erode, INDIA.
  2. 2Department of Pharmacy Practice, Drug and Poison Information Center, KMCH College of Pharmacy, Coimbatore, INDIA.
  3. 3Department of Neurology, Kovai Medical Center and Hospital, Coimbatore, INDIA.

CORRESPONDENCE

M. Ahamada Safna Mariyam

Department of Pharmacy Practice, Nandha College of Pharmacy, Erode, INDIA.

Safna86@gmail.com

Volume 5, Issue 1 · pp. 30–31 · PUBLISHED · DOI: 10.1016/j.jyp.2012.12.001

View on JYP original site ↗

ABSTRACT

Topiramate, a sulfa-derivative monosaccharide was originally developed as a hypoglycemic agent, but was found to be devoid of hypoglycemic activity, and later, it was approved in 1995 in the UK as adjunctive treatment for partial-onset seizures.1 Topiramate with several mechanisms of actions, by its long half-life, high oral bioavailability, low protein binding, renal elimination, and with little or no hepatic metabolism, proves to be an ideal migraine prophylaxis medication, and was approved in 2004 by the Food and Drug Administration.2,3

KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Mariyam, M. A. S., Sen, S., & Vijayan, K. (). Topiramate: Safety in migraine patients. Journal of Young Pharmacists, 5(1), 30–31. https://doi.org/10.1016/j.jyp.2012.12.001